Similar trends were observed on T cells isolated from healthy donors and patients with RRMS, although CD46 costimulation of MS T cells revealed a reduced modulation, likely reflecting the altered CD46 pathway in these patients (16, 18). This evidence concerns the gene CD46 and myeloid sarcoma.